Lupin plans to launch 3-4 generic drugs in U.S. by end-March
MUMBAI (Reuters) - Lupin Ltd(LUPN.NS), India's fourth largest drugmaker by sales, expects to launch three to four new generic drugs in its key U.S. market by March end, its Group President Nilesh Gupta said on Thursday.
The Mumbai-based drugmaker has so far launched six products in this fiscal year in the United States, which generates about 42 percent of its total formulation sales.
The drugmaker earlier reported a forecast-beating 42.6 percent rise in quarterly net profit to 3.35 billion rupees.
(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Two Ukrainian fighter jets shot down over rebel-held territory
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand
- UPDATE 2-Concordia finally heads for scrapyard after massive salvage operation
- U.N.'s Pillay says Israel may be committing war crimes
- UPDATE 5-TransAsia Airways plane crashes in typhoon-hit Taiwan, killing 47
India will not support a trade facilitation protocol ahead of a July 31 deadline unless its concerns about subsidies are met, two senior government officials said on Wednesday, sticking to a hard line critics say could derail a landmark global trade deal. Full Article
Bullish on Indian equities, but gains seen 'less sharp'- Goldman Sachs Full Article
Jet Airways chairman says looking to restructure debts, talking to bankers Full Article
Honda's India unit to account for 25 pct of Asia Pacific sales by March 2017 - exec Full Article